Roche Czech Republic made a net profit of CZK 51.0 mil under revenues of CZK 5,445 mil in 2015, down -46.3% and 24.8%, respectively, when compared to the last year. This translates into a net margin of 0.936%.
Historically, the firm’s net profit reached an all time high of CZK 135 mil in 2013 and an all time low of CZK 3.04 mil in 2003. Since 2010, the firm's net profit has increased -49.6% or -12.8% a year on average.
On the operating level, EBITDA reached CZK 209 mil, up -21.0% when compared to the previous year. Over the last five years, company's EBITDA has grown -3.77% a year on average.
As far as Roche Czech Republic's peers are concerned, Bayer Czech Republic posted net and EBITDA margin of 2.89% and 3.93%, respectively in 2015 and Amgen Czech Republic generated margins of 5.93% and 7.66%.